Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 5:51 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 1,102 matching trials from the live ClinicalTrials.gov search.
Conditions
Bladder Cancer, Urethral Cancer
Interventions
carboplatin, cisplatin, doxorubicin hydrochloride, methotrexate, paclitaxel, vinblastine sulfate
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
0 Years to 120 Years
Enrollment
490 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2007
U.S. locations
13
States / cities
Decatur, Georgia • Indianapolis, Indiana • Flemington, New Jersey + 9 more
Conditions
Bladder Cancer, Brain and Central Nervous System Tumors, Carcinoma of Unknown Primary, Extragonadal Germ Cell Tumor, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Ovarian Cancer, Sarcoma, Testicular Germ Cell Tumor, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
filgrastim, Amifostine, Carboplatin, Etoposide, Ifosfamide, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
3
States / cities
Boston, Massachusetts
Conditions
Biliary Carcinoma, Gall Bladder Carcinoma, Cholangiocarcinoma, Gastrointestinal Tumor
Interventions
Cisplatin, Gemcitabine, Copanlisib
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Non-Muscle Invasive Bladder Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8
Interventions
BCG Solution, Cystoscopy, Docetaxel, Gemcitabine, Home Health Encounter, Mitomycin, Questionnaire Administration
Biological · Procedure · Drug + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Jacksonville, Florida
Conditions
Hematuria, Bladder Cancer
Interventions
Valproic Acid
Drug
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
21 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Syracuse, New York
Conditions
Bladder Cancer
Interventions
ADXBLADDER
Diagnostic Test
Lead sponsor
Arquer Diagnostics Ltd
Industry
Eligibility
22 Years and older
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
13
States / cities
Denver, Colorado • Daytona Beach, Florida • Jeffersonville, Indiana + 10 more
Conditions
Non-Muscle Invasive Bladder Carcinoma
Interventions
Accelerometry, BCG Solution, Electronic Health Record Review, Patient Discharge, Survey Administration
Procedure · Biological · Other + 1 more
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Muscle Invasive Bladder Carcinoma, Stage III Bladder Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8
Interventions
Intensity-Modulated Radiation Therapy, Volume Modulated Arc Therapy, Radiosensitizing Agent, Radical Cystectomy, Pelvic Lymphadenectomy, Stereotactic Body Radiation Therapy, Computed Tomography, Positron Emission Tomography, Magnetic Resonance Imaging, Transurethral Resection of Bladder Tumor, Cystoscopy, Biospecimen Collection, Questionnaire Administration
Radiation · Drug · Procedure + 1 more
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Seattle, Washington
Active, not recruiting Phase 1 Interventional Results available

MAGE-A4ᶜ¹º³²T for Multi-Tumor

NCT03132922
Conditions
Urinary Bladder Cancer, Melanoma, Head and Neck Cancer, Ovarian Cancer, Non-Small Cell Lung Cancer, Esophageal Cancer, Gastric Cancer, Synovial Sarcoma, Myxoid Round Cell Liposarcoma, Gastroesophageal Junction
Interventions
Autologous genetically modified MAGE-A4ᶜ¹º³²T cells, Autologous genetically modified MAGE-A4c1032T cells combined with low dose radiation
Genetic · Radiation
Lead sponsor
USWM CT, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2032
U.S. locations
10
States / cities
Miami, Florida • Tampa, Florida • St Louis, Missouri + 6 more
Conditions
Stage 0is Bladder Urothelial Carcinoma, Stage I Bladder Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma, Stage III Bladder Urothelial Carcinoma
Interventions
Questionnaire Administration, Radical Cystectomy
Other · Procedure
Lead sponsor
University of Southern California
Other
Eligibility
Not listed
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Carcinoma, Transitional Cell
Interventions
Oxaliplatin with Gemcitabine
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Orange, California
Conditions
Urothelial Cancer, Advanced/Metastatic Urothelial Cancer, Urothelial Carcinoma
Interventions
PF-08634404, Enfortumab Vedotin
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
164
States / cities
Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 100 more
Conditions
Bladder Cancer, Prostate Cancer, Kidney Cancer, Pelvic Tumor, Interstitial Cystitis, Congenital Abnormalities, End Stage Renal Disease, Renal Tumor, Kidney Injury
Interventions
RAS Prostatectomy, RAS Cystectomy, RAS Nephrectomy
Device
Lead sponsor
Medtronic - MITG
Industry
Eligibility
22 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
6
States / cities
Duarte, California • Chicago, Illinois • New York, New York + 3 more
Conditions
Non-metastatic Bladder Cancer
Interventions
Cannabigerol
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Palo Alto, California
Conditions
Bladder Cancer, Non-muscle Invasive Bladder Cancer
Interventions
Not listed
Lead sponsor
Photocure
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
5
States / cities
Tampa, Florida • Iowa City, Iowa • Ann Arbor, Michigan + 2 more
Not listed No phase listed Observational Accepts healthy volunteers

The Molecular Predisposition to Hereditary Nonpolyposis Colon Cancer (HNPCC)

NCT01447199
Conditions
Bladder Cancer, Colorectal Cancer, Endometrial Cancer, Kidney Cancer, Skin Cancer, Uterus Cancer
Interventions
Health and Diet Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1994 – 2020
U.S. locations
1
States / cities
Houston, Texas
Conditions
Advanced Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Recurrent Urothelial Carcinoma, Stage III Bladder Urothelial Carcinoma AJCC v6 and v7, Stage IV Bladder Urothelial Carcinoma AJCC v7, Unresectable Urothelial Carcinoma
Interventions
Eribulin Mesylate, Laboratory Biomarker Analysis, Pharmacological Study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2027
U.S. locations
26
States / cities
Beverly Hills, California • Duarte, California • Lancaster, California + 21 more
Conditions
Advanced Cancer
Interventions
Avelumab, Utomilumab, PF-04518600, PD 0360324, CMP-001
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
409 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
57
States / cities
Encinitas, California • La Jolla, California • Los Angeles, California + 23 more
Conditions
Bladder Cancer
Interventions
ERAS Protocol, Standard of Care
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Stage IV Bladder Cancer
Interventions
Antineoplaston therapy (Atengenal + Astugenal)
Drug
Lead sponsor
Burzynski Research Institute
Other
Eligibility
18 Years to 99 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 1998
U.S. locations
1
States / cities
Houston, Texas
Conditions
Hematological Neoplasms, Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Lymphoma, Multiple Myeloma, Acute Myeloid Leukemia, Leukemia, Myelodysplastic Syndromes, Neoplasms, Melanoma, Breast Cancer, Metastatic Breast Cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Renal Cell Carcinoma, Glioblastoma Multiforme, Osteosarcoma, Sarcoma, Thyroid Cancer, Genitourinary
Interventions
CC-486, Vidaza
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
10
States / cities
Scottsdale, Arizona • Tucson, Arizona • Iowa City, Iowa + 6 more
Conditions
Bladder Carcinoma
Interventions
Intravesical BCG and EMDA/MMC
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 89 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Phoenix, Arizona • Aurora, Colorado
Active, not recruiting Phase 1Phase 2 Interventional

A Beta-only IL-2 ImmunoTherapY Study

NCT05086692
Conditions
Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer, Non-Small Cell Lung Cancer Squamous, Non-Small Cell Lung Cancer Non-squamous, Colorectal Cancer (MSI-H), Gastric Cancer, Cervical Cancer, Basal Cell Carcinoma, Bladder Cancer, Merkel Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck, Cutaneous Squamous Cell Carcinoma, Pleural Mesothelioma, Esophageal Cancer, Endometrial Carcinoma, Solid Tumor, Solid Tumor, Adult, MSI-H Solid Malignant Tumor, Cancer With A High Tumor Mutational Burden, Epithelial Ovarian Carcinoma, Primary Peritoneal Cancer, Gastroesophageal Junction (GEJ) Cancer, Acral Melanoma, Mucosal Melanoma, Cutaneous Melanoma, DMMR Solid Malignant Tumor, Fallopian Tube Cancer, Ovarian Cancer, MSI-H Cancer, DMMR Cancer, Pancreas Adenocarcinoma (MSI-H), Skin Cancer, Viral Cancer, Cervical Cancers, Endometrial Cancer
Interventions
MDNA11, Pembrolizumab (KEYTRUDA®)
Drug
Lead sponsor
Medicenna Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
7
States / cities
San Diego, California • San Francisco, California • Santa Monica, California + 4 more
Conditions
Bladder Urothelial Carcinoma
Interventions
Stereotactic body radiotherapy, Cemiplimab, Cemiplimab and Fianlimab, Radical cystectomy
Radiation · Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more